ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
Summary: Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an indiv...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-05-01
|
| Series: | Cell Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124722005216 |
| _version_ | 1828824296070316032 |
|---|---|
| author | Jeffrey Seow Carl Graham Sadie R. Hallett Thomas Lechmere Thomas J.A. Maguire Isabella Huettner Daniel Cox Hataf Khan Suzanne Pickering Rebekah Roberts Anele Waters Christopher C. Ward Christine Mant Michael J. Pitcher Jo Spencer Julie Fox Michael H. Malim Katie J. Doores |
| author_facet | Jeffrey Seow Carl Graham Sadie R. Hallett Thomas Lechmere Thomas J.A. Maguire Isabella Huettner Daniel Cox Hataf Khan Suzanne Pickering Rebekah Roberts Anele Waters Christopher C. Ward Christine Mant Michael J. Pitcher Jo Spencer Julie Fox Michael H. Malim Katie J. Doores |
| author_sort | Jeffrey Seow |
| collection | DOAJ |
| description | Summary: Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1–2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response. |
| first_indexed | 2024-12-12T13:54:09Z |
| format | Article |
| id | doaj.art-c8a108ba74b346e4ac6cb60515b0c6d2 |
| institution | Directory Open Access Journal |
| issn | 2211-1247 |
| language | English |
| last_indexed | 2024-12-12T13:54:09Z |
| publishDate | 2022-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cell Reports |
| spelling | doaj.art-c8a108ba74b346e4ac6cb60515b0c6d22022-12-22T00:22:30ZengElsevierCell Reports2211-12472022-05-01395110757ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variantsJeffrey Seow0Carl Graham1Sadie R. Hallett2Thomas Lechmere3Thomas J.A. Maguire4Isabella Huettner5Daniel Cox6Hataf Khan7Suzanne Pickering8Rebekah Roberts9Anele Waters10Christopher C. Ward11Christine Mant12Michael J. Pitcher13Jo Spencer14Julie Fox15Michael H. Malim16Katie J. Doores17Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKHarrison Wing, Guy's and St Thomas’ NHS Trust, London, UKHarrison Wing, Guy's and St Thomas’ NHS Trust, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKInfectious Diseases Biobank, Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKPeter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UKPeter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UK; Harrison Wing, Guy's and St Thomas’ NHS Trust, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UKDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UK; Corresponding authorSummary: Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1–2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response.http://www.sciencedirect.com/science/article/pii/S2211124722005216CP: Immunology |
| spellingShingle | Jeffrey Seow Carl Graham Sadie R. Hallett Thomas Lechmere Thomas J.A. Maguire Isabella Huettner Daniel Cox Hataf Khan Suzanne Pickering Rebekah Roberts Anele Waters Christopher C. Ward Christine Mant Michael J. Pitcher Jo Spencer Julie Fox Michael H. Malim Katie J. Doores ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants Cell Reports CP: Immunology |
| title | ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants |
| title_full | ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants |
| title_fullStr | ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants |
| title_full_unstemmed | ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants |
| title_short | ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants |
| title_sort | chadox1 ncov 19 vaccine elicits monoclonal antibodies with cross neutralizing activity against sars cov 2 viral variants |
| topic | CP: Immunology |
| url | http://www.sciencedirect.com/science/article/pii/S2211124722005216 |
| work_keys_str_mv | AT jeffreyseow chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT carlgraham chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT sadierhallett chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT thomaslechmere chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT thomasjamaguire chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT isabellahuettner chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT danielcox chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT hatafkhan chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT suzannepickering chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT rebekahroberts chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT anelewaters chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT christophercward chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT christinemant chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT michaeljpitcher chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT jospencer chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT juliefox chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT michaelhmalim chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants AT katiejdoores chadox1ncov19vaccineelicitsmonoclonalantibodieswithcrossneutralizingactivityagainstsarscov2viralvariants |